When does this behavior become inappropriate, causing the patient to be labeled a drug seeker? Clearly, there is no agreement on the definition of drug see...When does this behavior become inappropriate, causing the patient to be labeled a drug seeker? Clearly, there is no agreement on the definition of drug seeking.
to doctors opioids Rx prescriptions drugseeking patients drug seeking pain medicine medication medications by avivagabriel on Aug 6, 2007, 7:36 PMscientists reported that a person's risk of a heart attack is doubled if he or she produces a particular version of FLAP, known more technically as 5-lipox...scientists reported that a person's risk of a heart attack is doubled if he or she produces a particular version of FLAP, known more technically as 5-lipoxygenase activating protein. A troublesome variant of this protein boosts production of the inflammat
to pathophysiology attacks chronic FLAP pharmaceutical inflammation cytokines heart leukotriene plaque genes inhibitor inflammatory drug 5-lipoxygenase interleukins by avivagabriel on Aug 6, 2007, 4:44 AM- to chronic compound950 inflammation acids development AUDA-BE pathophysiology research interleukins enzymes inhibitors epoxyeicosatrienoic drug inflammatory cytokines EETs by avivagabriel on Aug 6, 2007, 3:03 AM
- to pharmaceuticals PLoS industry medical drug_companies marketing openaccess companies drug publishing pharma open access open_access pharmaceutical journals pharmaceutical_industry bigpharma medicine by avivagabriel on Jul 28, 2007, 3:03 AM
The re-trial of pain doctor William Hurwitz came to an end in July 2007. The doctor's sentence was reduced to less than five years. He was originally given...The re-trial of pain doctor William Hurwitz came to an end in July 2007. The doctor's sentence was reduced to less than five years. He was originally given 25 years.
to hurwitz prison federal pain DEA medicine opiates prosecution sentencing opioids trial doctors physicians trafficking drug government by avivagabriel on Jul 27, 2007, 9:12 PMClinical trial was just put on hold (7/27/2007) due to adverse effects in one trial participant...
to trials agent clinical inflammatory rheumatology genetics drug development tgAAC94 anti-TNF-alpha arthritis targeted by avivagabriel on Jul 27, 2007, 2:27 PM- to development GSK MAPK mitogen-activated glaxo atherosclerosis p38 drug glaxosmithkline inhibitors kinase by avivagabriel on Jul 27, 2007, 1:29 PM
The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in t...The anti-inflammatory potential of an oral p38 MAPK inhibitor in humans in vivo suggests that p38 MAPK inhibitors may provide a new therapeutic option in the treatment of inflammatory diseases. Boehringer Ingelheim. 2002 Branger J, et al
to inhibitors immunology inflammatory drug ingelheim inflammation mitogen-activated cytokines kinase boehringer cardiology development cardiovascular protein p38 by avivagabriel on Jul 27, 2007, 12:43 AMp38 MAPK inhibitors represent a novel therapeutic approach to the treatment of restenosis associated with coronary angioplasty.
to cardiology cardiovascular glaxosmithkline pharmacology cytokines neointima mitogen-activated injury GSK remodeling protein MAPK drug fibronectin inflammation inflammatory inhibitors kinase 2001 novel development willette vascular by avivagabriel on Jul 27, 2007, 12:27 AM- to ampakine FDA modafinil alertness depression fatigue new ADD drug wakefulness development eugeroic ADHD adrafinil cephalon approved armodafinil by avivagabriel on Jul 23, 2007, 5:50 PM
Editorial on the "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial," which studied optimal medical treatment wi...Editorial on the "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial," which studied optimal medical treatment with or without percutaneous coronary intervention (PCI) for stable coronary disease.
to dinitrate ezetimibe clopidogrel leon plavix aggressive percutaneous simvastatin revascularization ischemia drug intervention amlodipine aspirin coronary myocardial isosorbide PCI metoprolol CAD boden controversy disease artery by avivagabriel on Jul 21, 2007, 6:32 AM- to artery dilators vasodilators venous pharmacology therapy infarct cardiology coronary depressant drug cardiovascular antiarrhythmics cardiac thrombolytics by avivagabriel on Jul 20, 2007, 7:44 AM
- to coronary pharmacology cardiology myocardial therapy cardiovascular drug infarction by avivagabriel on Jul 20, 2007, 7:33 AM
- to shire ADD ADHD pharmaceuticals development drug by avivagabriel on Jul 20, 2007, 2:52 AM
Optimal Medical Therapy With or Without PCI for Stable Coronary Disease =|= JAMA
to artery drug stenting cardiovascular angina cardiology medicine trials stents optimal therapy disease COURAGE PCI clinical coronary stable medical medications by avivagabriel on Jul 15, 2007, 3:16 AMVermont officials said drug company payments to psychiatrists in the state averaged $45,692 EACH!, up from $20,835 in 2005; this doesn't include drug sampl...Vermont officials said drug company payments to psychiatrists in the state averaged $45,692 EACH!, up from $20,835 in 2005; this doesn't include drug samples...
to free samples pharma drug companies pharmaceuticals drugs bigpharma psychiatrists payments antipsychotics gifts vermont development marketing by avivagabriel on Jun 28, 2007, 10:01 AM
::
avivagabriel ::
